Intra-ovarian injection of platelet-rich plasma in patients with premature ovarian insufficiency

Evaluation of intra-ovarian injection of platelet-rich plasma in patients with premature ovarian insufficiency; a clinical trial

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20080831001141N41

Enrollment

Registered

2023-02-08

Start date

2023-02-01

Completion date

Unknown

Last updated

2023-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Premature ovarian insufficiency. Female infertility, unspecified

Interventions

Intervention group: Intervention group: Platelet-rich plasma (PRP) injection will be done on day 8-12 of the menstrual cycle. PRP injection will be performed less than 15 minutes after its preparation

Eligibility

Sex/Gender

Female

Age

No minimum to 40 Years

Inclusion criteria

Inclusion criteria: Patients with premature ovarian insufficiency according to european society of human reproduction and embryology (ESHRE) guideline Body mass index < 35 Kg/m2 Normal karyotype Normal fragile X messenger ribonucleoprotein 1 (FMR1) gene

Exclusion criteria

Exclusion criteria: Endocrine, hematologic and autoimmune disorders Chromosomal and genetic abnormalities Cancer history Uterine anomalies Sever adenomyosis Endometriosis Hydrosalpinx Uterine fibromatosis

Design outcomes

Primary

Measure	Time frame
Serum level of follicle-stimulating hormone (FSH). Timepoint: 6-8 weeks after intra-ovarian injection of platelet-rich plasma. Method of measurement: Blood test.;Serum level of anti-mullerian hormone (AMH). Timepoint: 6-8 weeks after intra-ovarian injection of platelet-rich plasma. Method of measurement: Blood test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehri Mashayekhy

ROYAN Institute

dr.mashayekhy@yahoo.com+98 21 2356 2647

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026